Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TEVA
CUSIPN/A
Phone972-3926-7267
Debt
Debt-to-Equity Ratio1.86
Current Ratio1.03
Quick Ratio0.69
Price-To-Earnings
Trailing P/E Ratio6.53
Forward P/E Ratio9.61
P/E Growth2.8
Sales & Book Value
Annual Sales$22.39 billion
Price / Sales1.17
Cash Flow$7.1448 per share
Price / Cash3.59
Book Value$14.86 per share
Price / Book1.73
Profitability
EPS (Most Recent Fiscal Year)$3.93
Net Income$-16,265,000,000.00
Net Margins-47.98%
Return on Equity19.92%
Return on Assets5.02%
Miscellaneous
Employees51,792
Outstanding Shares1,016,880,000
Market Cap$22.86 billion
Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions
What is Teva Pharmaceutical Industries' stock symbol?
Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries declared a quarterly dividend on Thursday, November 2nd. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.
How were Teva Pharmaceutical Industries' earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its quarterly earnings results on Thursday, August, 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.64 by $0.14. The firm earned $4.70 billion during the quarter, compared to analysts' expectations of $4.75 billion. Teva Pharmaceutical Industries had a negative net margin of 47.98% and a positive return on equity of 19.92%. The business's quarterly revenue was down 17.8% compared to the same quarter last year. During the same period last year, the firm earned $1.02 EPS. View Teva Pharmaceutical Industries' Earnings History.
When is Teva Pharmaceutical Industries' next earnings date?
What price target have analysts set for TEVA?
26 brokers have issued 12 month target prices for Teva Pharmaceutical Industries' stock. Their predictions range from $11.00 to $38.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $20.42 in the next year. This suggests that the stock has a possible downside of 20.4%. View Analyst Price Targets for Teva Pharmaceutical Industries.
What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?
26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 6 sell ratings, 14 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.
What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
- 1. Cantor Fitzgerald analysts commented, "We rate TEVA 12-month price target of $25. We like Teva’s stock and believe that there is a lot of value to be unlocked, but that it will take time for new leadership to return the business to growth. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (8/16/2018)
- 2. Mizuho analysts commented, "We will update our thoughts after the earnings call, which is underway." (8/2/2018)
- 3. According to Zacks Investment Research, "Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva is progressing well on its strategic/restructuring initiatives to revive growth. After declining sharply in 2017, Teva’s shares have also picked up this year. Teva has a new organizational structure in place, is closing plants, cutting down its generics portfolio, divesting non-core assets, eliminating low-value R&D projects, and aims to cut its global workforce by more than 25% over the next two years. Teva expects to save almost $3 billion by the end of 2019 from these initiatives. Its financial position seems more stable than before as it is regularly paying down debt." (7/9/2018)
- 4. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
Are investors shorting Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 37,244,528 shares, a drop of 11.3% from the July 13th total of 42,005,618 shares. Based on an average trading volume of 6,526,679 shares, the days-to-cover ratio is presently 5.7 days. View Teva Pharmaceutical Industries' Current Options Chain.
Who are some of Teva Pharmaceutical Industries' key competitors?
Some companies that are related to Teva Pharmaceutical Industries include Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF) and GRIFOLS S A/S (GRFS).
Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the folowing people:
- Mr. Kåre Schultz, Pres, Chief Exec. Officer & Director (Age 57)
- Mr. Michael McClellan, Exec. VP & CFO (Age 47)
- Mr. Mark Sabag, Exec. VP of Global HR (Age 47)
- Mr. Kevin C. Mannix, Head of Global Investor Relations & VP
- Mr. David M. Stark, Exec. VP & Chief Legal Officer (Age 49)
Has Teva Pharmaceutical Industries been receiving favorable news coverage?
Press coverage about TEVA stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teva Pharmaceutical Industries earned a news and rumor sentiment score of 0.05 on Accern's scale. They also gave news articles about the company an impact score of 47.12 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Teva Pharmaceutical Industries.
Who are Teva Pharmaceutical Industries' major shareholders?
Teva Pharmaceutical Industries' stock is owned by a number of of retail and institutional investors. Top institutional investors include Northern Cross LLC (2.21%), FMR LLC (2.02%), Polaris Capital Management LLC (0.89%), PointState Capital LP (0.65%), OppenheimerFunds Inc. (0.42%) and Renaissance Technologies LLC (0.40%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Richard Daniell, Roberto Mignone and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.
Which institutional investors are selling Teva Pharmaceutical Industries stock?
TEVA stock was sold by a variety of institutional investors in the last quarter, including Northern Cross LLC, FMR LLC, First Manhattan Co., BlueMountain Capital Management LLC, Polaris Capital Management LLC, Migdal Insurance & Financial Holdings Ltd., Schroder Investment Management Group and Harel Insurance Investments & Financial Services Ltd.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Iris Beck Codner, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
Which institutional investors are buying Teva Pharmaceutical Industries stock?
TEVA stock was purchased by a variety of institutional investors in the last quarter, including PointState Capital LP, Point72 Asset Management L.P., Renaissance Technologies LLC, Caisse DE Depot ET Placement DU Quebec, Miller Value Partners LLC, Strs Ohio, Jafra Capital Management LP and Acadian Asset Management LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
How do I buy shares of Teva Pharmaceutical Industries?
Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries' stock price today?
One share of TEVA stock can currently be purchased for approximately $25.65.
How big of a company is Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a market capitalization of $22.86 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.
How can I contact Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]
MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
